Peptic ulcers, recognized for their erosive impact on the gastrointestinal
mucosa, present a considerable challenge in gastroenterology. Epidemiological
insights underscore the global prevalence of peptic ulcers, affecting 5–10+% of
individuals, with a yearly incidence of 0.3 to 1.9 cases per thousand. Recent
decades have witnessed a decline in complications, attributed to improved
diagnostics and therapeutic advancements. The review deepens into H.
pylori-associated and NSAID-induced ulcers, emphasizing their distinct
prevalence in developing and industrialized nations, respectively. Despite
advancements, managing peptic ulcers remains challenging, notably in H.
pylori-infected individuals facing recurrence and the rise of antibiotic
resistance. The pathophysiology unravels the delicate balance between protective
and destructive factors, including the intricate molecular mechanisms involving
inflammatory mediators such as TNF-α, ILs, and prostaglandins. Genetic and
ethnic factors, rare contributors, and recent molecular insights further enhance
our understanding of peptic ulcer development. Diagnostic approaches are
pivotal, with upper gastrointestinal endoscopy standing as the gold standard.
Current treatment strategies focus on H. pylori eradication, NSAID
discontinuation, and proton pump inhibitors. Surgical options become imperative
for refractory cases, emphasizing a comprehensive approach. Advances include
tailored H. pylori regimens, the emergence of vonoprazan, and ongoing
vaccine development. Challenges persist, primarily in antibiotic resistance,
side effects of acid suppressants, and translating natural compounds into
standardized therapies. Promising avenues include the potential H. pylori
vaccine and the exploration of natural compounds, with monoterpenes showing
therapeutic promise. This review serves as a compass, guiding healthcare
professionals, researchers, and policymakers through the intricate landscape of
peptic ulcer management.